NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability
01 Febbraio 2024 - 12:00PM
Business Wire
Three customers will present inaugural studies
powered by the novel CosMx Whole Transcriptome Panel during annual
AGBT meeting
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider
of life science tools for discovery and translational research,
today announced the commercial availability of the CosMx™ Human 6K
Discovery Panel, the industry’s first single-cell spatial panel
enabling research scientists to measure over 6,000 RNA targets,
representing nearly every human biological pathway. Building on
this breakthrough product developed for the CosMx Spatial Molecular
Imager (SMI), NanoString and independent researchers will also
highlight recently achieved whole transcriptome imaging capability
- the pinnacle of spatial biology - at the Advances in Genome
Biology and Technology (AGBT) General Meeting, February 5-8 in
Orlando, Florida.
Under the banner, “Plex YES!”, a theme inspired by customer
reactions to the high plex CosMx Human 6K Discovery Panel,
NanoString team members and early access researchers will highlight
the CosMx SMI’s expanded capabilities with the official product
launch at the annual AGBT meeting. These will include showcasing
superior cell segmentation, genomic breadth, and capacity to
profile genes across nearly every biological pathway and over 400
ligand-receptor pairs.
With the recently announced achievement of the whole
transcriptome prototype panel on the CosMx SMI, researchers can now
analyze almost 19,000 genes at true single-cell and subcellular
resolution. Dr. Miranda Orr of Wake Forest University School of
Medicine, Dr. Holger Heyn of Centro Nacional de Análisis Genómico,
and Dennis Hua Gong of Massachusetts General Hospital and Harvard
University will present novel research representing the first
studies powered by whole transcriptome imaging.
"The CosMx Whole Transcriptome Panel is the ultimate tool for
spatial biology; it resulted in new discoveries on my first run. I
know I’m getting the maximum amount of data possible from precious
tissue samples. It eliminates the tradeoff between resolution and
plex," said Miranda Orr, Ph.D., of Wake Forest University School of
Medicine. Following early access to the product, Dr. Orr observed,
"The panel is advancing the understanding of senescent cells and
unraveling the genomic signatures underlying their role in
Alzheimer's Disease.”
Describing the CosMx Whole Transcriptome Panel as
“groundbreaking technology,” Dr. Heyn predicts, “it will change the
way my lab addresses the most challenging research questions, and
undoubtedly, it will advance our understanding of colorectal
cancer, paving the way for significant improvements in diagnostics
and targeted therapies."
NanoString’s spatial solutions will be featured in ten
AGBT-accepted abstracts, including two independent academic
researchers presenting data on the company’s ground-breaking
innovation, whole transcriptome imaging on the CosMx SMI.
CosMx Whole Transcriptome Panel:
- “Spatio-temporal dissection of colorectal cancer initiation
using Whole Transcriptome imaging,” presented by Holger Heyn,
Ph.D., of Centro Nacional de Análisis Genómico, Tuesday, February
6, 8:50-9:10 PM ET.
- “Integration of Live Cell Holotomography and Single Cell
Spatial Transcriptomics to Visualize Acquired and Intrinsic
Resistance to Targeted Therapy,” single cell analysis, integrating
in-depth analysis of cell morphologies via label-free live cell
holotomography leveraging the CosMx SMI’s Whole Transcriptome
analysis to examine cell phenotypes and genetic response to
perturbations, a poster flash talk presented by Dennis Hua Gong, of
Massachusetts General Hospital and Harvard University, Tuesday,
February 6 at 11:25 AM ET.
- “Ultra-high plex single-cell spatial multi-omic imaging of tau
neuropathology in human brain sections,” a 64-plex protein and
whole transcriptome RNA imaging study accomplished from the same
sample revealing spatial correlations of tau proteins with gene
expression in Alzheimer’s disease, presented by Miranda Orr, Ph.D.,
of Wake Forest University School of Medicine, Wednesday, February
7, 8:50-9:10 PM ET.
CosMx Human 6K Discovery Panel & CosMx Whole
Transcriptome Panel:
- “NanoString Spatial Biology Roadmap: The Holy Grail of Spatial
is Here,” presented by Joseph Beechem, Ph.D., Chief Scientific
Officer, NanoString, Wednesday, February 7, 3:35-3:50 PM ET.
GeoMx DSP and CosMx SMI:
- “The Spatial Atlas of Human Anatomy (SAHA) project: unveiling
cellular landscapes and orchestrating a new paradigm in precision
medicine,” a foundational database for benchmarking spatial
medicine, an update on the first samples analyzed using GeoMx
Digital Spatial Profiler and CosMx SMI, presented by Jiwoon Park,
Ph.D., of Weill Cornell Medicine, Tuesday, February 6, 4:20-4:40 PM
ET.
To celebrate the launch and commercial shipment of the CosMx
Human 6K Discovery Panel, NanoString invites AGBT attendees to
participate in “6K All Day!” and welcomes AGBT attendees to visit
its booth, Curacao 1. For those unable to attend AGBT, NanoString
will host a webinar with Dr. Beechem that will include his AGBT
workshop and live Q & A with Joe.
NanoString plans to make the CosMx Human Whole Transcriptome
panel commercially available in 2025.
About NanoString
NanoString Technologies, a leader in spatial biology, offers an
ecosystem of innovative discovery and translational research
solutions, empowering our customers to map the universe of biology.
The GeoMx® Digital Spatial Profiler is a flexible and consistent
solution combining the power of whole tissue imaging with gene
expression and protein data for spatial whole transcriptomics and
proteomics. The CosMx™ Spatial Molecular Imager is a single-cell
imaging platform powered by spatial multiomics enabling researchers
to map single cells in their native environments to extract deep
biological insights and novel discoveries from one experiment. The
AtoMx™ Spatial Informatics Platform is a cloud-based informatics
solution with advanced analytics and global collaboration
capabilities, enabling powerful spatial biology insights anytime,
anywhere. At the foundation of our research tools is our nCounter®
Analysis System, which offers a secure way to easily profile the
expression of hundreds of genes, proteins, miRNAs, or copy number
variations, simultaneously with high sensitivity and precision.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include statements regarding our plans to commercially
launch and ship new product offerings in the future and
expectations about demand for our products. Such statements are
based on current assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially.
These risks and uncertainties, many of which are beyond our
control, include market acceptance of our products; adverse
conditions in the general domestic and global economic markets; the
effects of ongoing litigation; the impact of competition; the
impact of expanded sales, marketing, and product development on
operating expenses; delays or other unforeseen problems with
respect to manufacturing and product development; as well as the
other risks set forth in our filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. NanoString Technologies disclaims any
obligation to update these forward-looking statements.
NanoString, NanoString Technologies, the NanoString logo, GeoMx,
AtoMx and nCounter are trademarks or registered trademarks of
NanoString Technologies, Inc. in various jurisdictions.
This news release may include information regarding CosMx™ SMI
products for RNA detection, products that are not available in the
member states of the European Unified Patent Court. Such
limitations are further described here.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240201133172/en/
Meg O’Conor Director of Public Relations MOConor@NanoString.com
Phone: 206-735-8495
Grafico Azioni NanoString Technologies (NASDAQ:NSTG)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni NanoString Technologies (NASDAQ:NSTG)
Storico
Da Gen 2024 a Gen 2025